OrbiMed’s Cytokinetics CYTK Stock Holding History

OrbiMed’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,077,000	Closed	-$35.6M	–	115
2025 Q2	$35.6M	Sell	1,077,000 -432,205	-29%	-$15M	0.89%	29
2025 Q1	$60.7M	Sell	1,509,205 -74,800	-5%	-$3.44M	1.45%	22
2024 Q4	$74.5M	Buy	1,584,005 +817,099	+107%	+$42.4M	1.53%	22
2024 Q3	$40.5M	Sell	766,906 -46,000	-6%	-$2.56M	0.74%	41
2024 Q2	$44M	Buy	812,906 +130,206	+19%	+$7.86M	0.87%	35
2024 Q1	$47.9M	Buy	+682,700	New	+$52.8M	0.88%	40

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

OrbiMed's CYTK Position: Q3 2025 in Review

OrbiMed sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 1,077,000 shares — an estimated $35.6M sold.

OrbiMed first reported a position in CYTK in Q1 2024 and held it in 6 quarters. The position peaked at $74.5M in Q4 2024. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

OrbiMed reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
OrbiMed sold 1,077,000 Cytokinetics shares in Q3 2025, an estimated $35.6M.
OrbiMed first reported a position in Cytokinetics in Q1 2024 and held it in 6 quarters.
OrbiMed's Cytokinetics position peaked at $74.5M in Q4 2024.
380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.